Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionSubarachnoid Hemorrhage (SAH) resulting from the spontaneous rupture of an aneurysm is a rare and highly debilitating condition.

Hemorrhage 40

Hemorrhage Aneurysm Cardiac Arrest Myocardial Infarction 40

Cardiology Update

FEBRUARY 11, 2024

Patients were evaluated based on a composite outcome of all-cause mortality, stroke, or myocardial infarction. Bioprosthetic valve dysfunction (BVD) was categorized into structural valve deterioration (SVD), non-structural valve dysfunction (NSVD), clinical valve thrombosis, or endocarditis.

Aortic valve 124

Aortic valve Aortic Outcomes Thrombosis 124

Circulation

FEBRUARY 26, 2024

Patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention were randomly assigned by center to receive low-dose PPA or matching placebo for at least 48 hours. Circulation, Ahead of Print. mg·kg·h of bivalirudin intravenously). mg·kg·h of bivalirudin intravenously).

Myocardial Infarction 40

Myocardial Infarction Academic Thrombosis STEMI 40

Frontiers in Cardiovascular Medicine

JANUARY 7, 2024

Background Stent thrombosis (ST) is an uncommon but serious complication of stent implantation. age, sex, ACS presentation, history of hypertension, smoking, diabetes, prior myocardial infarction (MI), heart failure, prior ischemic stroke, and cancer], laboratory tests [i.e.,

Stent 64

Stent Stents Thrombosis Myocardial Infarction 64

Stroke Journal

FEBRUARY 1, 2024

Stroke, Ahead of Print. Primary end point was a composite of ischemic stroke, myocardial infarction, or other arterial thrombotic events. CONCLUSIONS:Intracerebral hemorrhage survivors are at high long-term risk of arterial thrombosis. Arterial thrombotic events occurred in 169 (9.7%) patients.

Thrombosis 40

Thrombosis Hemorrhage Coronary Artery Disease Myocardial Infarction 40

Circulation

NOVEMBER 11, 2024

vs 6.0%), stroke (RR=1.02; 95% CI [0.38, 2.75]; p =0.97; 2.0% vs 13.6%), any stent thrombosis (RR=1.42; 95% CI [0.35, 5.72]; p=0.62; 2.2% vs 6.0%), stroke (RR=1.02; 95% CI [0.38, 2.75]; p =0.97; 2.0% vs 13.6%), any stent thrombosis (RR=1.42; 95% CI [0.35, 5.72]; p=0.62; 2.2%

Coronary Artery Disease 40

Coronary Artery Disease Myocardial Infarction STEMI Thrombosis 40

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page AWP291-AWP291, February 1, 2025.

Cancer 40

Cancer Stroke Strokes Myocardial Infarction 40

Cardiology Update

FEBRUARY 14, 2024

In the early years of percutaneous coronary intervention (PCI), studies indicated a heightened risk of major adverse cardiac events (MACE) in patients with reduced left ventricular ejection fraction (LVEF), involving outcomes such as death, Q-wave myocardial infarction (MI), stent thrombosis, and repeat revascularization.

Myocardial Infarction 52

Myocardial Infarction Coronary Artery Disease Thrombosis Research 52

Open Heart

DECEMBER 29, 2022

There was also no difference in the rate of bleeding between PFT-guided and standard therapies (major bleeding: RR=0.97, p=0.78, minor bleeding: RR=0.89, p=0.19 and any bleeding: RR=1.04, p=0.33).

Myocardial Infarction 52

Myocardial Infarction Thrombosis Stents Stent 52

Circulation

OCTOBER 24, 2023

The primary endpoint was the net clinical benefit as a composite of all-cause death, myocardial infarction, definite or probable stent thrombosis, stroke, and major bleeding at 1 year after the index procedure in the intention-to-treat population. 0.80];P<0.001 for noninferiority;P=0.002 for superiority).

Stent 40

Stent Stents Myocardial Infarction Thrombosis 40

DAIC

JANUARY 23, 2024

3 Patients with ASCVD are at a higher risk for major adverse cardiovascular events (MACE) including heart attack or myocardial infarction (MI), stroke, and cardiovascular (CV) death.4 mg) to reduce the risks of heart attack, stroke, coronary revascularization, and CV death.29 4 In the U.S. As of June 2023, the U.S.

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111

Journal of Cardiovascular Pharmacology

MAY 2, 2024

The primary outcome was major adverse cardiac and cerebrovascular event (MACCE), namely a composite of death from cardiovascular causes, myocardial infarction (MI), stroke, stent thrombosis within 12 month. Patient characteristics and clinical outcomes were collected via electronic medical record system.

Outcomes 40

Outcomes Myocardial Infarction Thrombosis Academic 40

Circulation

NOVEMBER 23, 2023

3.30]) and subacute definite or probable stent thrombosis (0.58% and 0.17%; hazard ratio, 3.40 [95% CI, 1.26–9.23]) years; men, 76.6%; acute coronary syndrome, 75.0%). There was no difference in net adverse clinical outcomes and each component of coprimary cardiovascular end point.

Stent 40

Stent Stents Thrombosis Myocardial Infarction 40

Cardiology Update

APRIL 9, 2024

EMPACT-MI 1 ( NCT04509674 ) studied the effects of empagliflozin in patients who have experienced myocardial infarction (MI). The primary endpoint consisted of a composite of all-cause mortality, MI, stroke, coronary revascularization, or hospitalization for unstable angina. vs. 6.2%) and stroke (2.9%

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. of all strokes [1, 2]. These strokes primarily occur in the anterior spinal cord artery (ASA) and/or the posterior spinal cord artery (PCA) territory and can have widely variable clinical presentation.

Ischemia 40

Ischemia Myocardial Infarction Thrombosis Stroke 40

Open Heart

MAY 12, 2023

Objective Antithrombotic therapy is essential for patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) because of the high risk of thrombosis, whereas a combination of antiplatelets and anticoagulants is associated with a high risk of bleeding.

Coronary Artery Disease 52

Coronary Artery Disease Atrial Fibrillation Myocardial Infarction Blood Pressure 52

Frontiers in Cardiovascular Medicine

JANUARY 8, 2025

The primary focus is on the incidence of major adverse cardiovascular events (MACE), thrombosis, bleeding events, and adverse reactions. However, the effects of both treatments on efficacy outcomes, including MACE, myocardial infarction, angina, mortality, and thrombotic events, were similar.

Cerebrovascular Disease 52

Cerebrovascular Disease Cardiovascular Disease Myocardial Infarction Angina 52